• The G9a methyltransferase inhibitor UNC0638 increased pancellular expression of HbF to levels greater than 30% in adult human erythroblasts.
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Introduction
In humans, the β-globin cluster contains fetal Expression of β-globin genes is regulated by physical interactions between gene promoters and the locus control region (LCR) enhancer. 2, 3 Experiments using RNAi have shown that this interaction is facilitated by the LDB1/LMO2/GATA-1/TAL1 erythroid specific protein complex (LDB1 complex). [4] [5] [6] The LDB1 complex occupies the LCR and the β-globin gene promoter and provides chromatin loop formation between them through interaction between LDB1 homodimerization domains. 7, 8 Mouse β-globin genes are also regulated by the G9a/EHMT2 H3K9 histone methyltransferase. 9, 10 G9a contains a SET domain responsible for histone H3K9 mono-and dimethylation associated with repression of gene expression. 11 Interestingly, recent observations support the view that G9a can play a role in activation of gene expression independently from its repressive methyltransferase activity. 12 In human cells, G9a functions as a stable heteromeric complex with a related protein, GLP (EHMT1 qRT-PCR. RNA samples were prepared and analyzed by RT-qPCR as described previously. 17 Primers, probes and conditions used to perform RT-qPCR assays for α -globin, β-globin and γ-globin gene transcripts were previously described. 19 Analysis of gene expression was carried out using the following Assays-on-Demand Gene Expression Products (Applied Biosystems, Grand
Island, NY): TAL1 (Hs01097987_m1); LMO2 (Hs00153473_m1); LDB1 (Hs01597578_m1); Chromosome conformation capture. 3C assays were performed as described using EcoRI (New England Biolabs, Ipswich, MA) cleavage. 8 Relative cross-linking between the anchor fragment and fragments of interest were analyzed by SYBR Green real-time qPCR using published primers. 21 The primer used for detecting interaction with 
Results

G9a represses fetal hemoglobin production during adult human erythropoiesis.
A threephase culture system was used for these studies as previously described. 17 During the first phase of culture (days 0-7), the CD34 + cells differentiate into progenitor cell populations that include compound at a concentration of 1.0µM was added with fresh culture medium to a single phase (culture days 0, 7 or 14), or added to the fresh medium in all three culture phases.
The addition of UNC0638 caused the most pronounced increase in the percent of HbF during phase II and the effect was no greater if the drug was present throughout the culture period ( Figure 1A ). There was a modest rise in HbF with UNC0638 present during phase I only compared to control; however, when added during the third phase, there was no significant change in HbF when compared to the control. Based on the screening experiments, a dosed titration was performed during phase II with concentrations ranging from 4.0µM to 0.031µM UNC0638. Doses of 2.0µM and 4.0µM were cytotoxic to the cells, preventing further studies (data not shown). As the UNC0638 concentration was titrated from 0.031µM to 1. Moreover, the strongest (35-fold) decrease in H3K9me2 was observed at the activated γ -globin gene promoters, consistent with the absence of this mark at active human fetal globin genes. 24 Additionally, H3K27me2 distribution was investigated, as it has been reported to serve a repressive role with respect to ε y-globin expression in mouse MEL cells, which is relieved by G9a reduction. 9 H3K27me2 was reduced across the locus in UNC0638 treated cells but to a more modest extent than for H3K9me2 and can still be detected at the γ-globin promoter ( Figure 3B ).
UNC0638 treatment during phase I also reduced H3K9me2 occupancy when measured on culture day 7 (Supplemental Figure S3) . However, after seven additional culture days in the absence of UNC0638, reductions in H3K9me2 occupancy relative to controls were no longer detected.
Given that G9a can also act as an activator of gene expression independently from its methyltransferase activity, 9, 12 we investigated how UNC0638 treatment affects G9a distribution 
G9a inactivation induces
γ -globin/LCR looping. Given the role of the LDB1 complex in facilitating long-range interactions in the β-globin locus 8, 21, 27 and its redistribution after G9a inactivation, looping between an anchor LCR fragment and the β-globin genes was examined using the 3C assay. UNC0638 treatment established an interaction between the LCR and the γ -globin genes that is absent in control cells ( Figure 5 ). Additionally, interactions between the LCR and adult β-globin genes were significantly decreased after treatment, consistent with establishment of an overall locus looping configuration favoring LCR interaction with the fetal genes at the expense of the adult globin genes. In summary, inactivation of G9a 
Discussion
Here we show that inactivation of G9a methyltransferase activity in differentiating adult erythroid cells by UNC0638 causes a dose-dependent accumulation of HbF. Unexpectedly, the response to treatment with UNC0638 was highly-dependent upon the differentiation stage of the cells. The strongest accumulation of HbF was detected when UNC0638 was applied during phase II (days [7] [8] [9] [10] [11] [12] [13] [14] suggesting that the G9a dependent decision regarding whether fetal or adult hemoglobin would be produced is made at the period of time when erythroid differentiation is induced by addition of erythropoietin. Cells treated with UNC0638 during phase III did not increase HbF, suggesting that the pattern of globin gene transcription is not reversible during this stage or that the robustness of globin gene transcription is diminishing or both. There was a small increase in HbF observed at culture day 21 for cells incubated with UNC0638 during the first 7 days of culture (phase I) when CD34 + cells are differentiating into CD36 + erythroblasts but before the onset of high-level globin gene transcription. This result may be explained by the observation that although UNC0638 effectively reduced H3K9me2 across the β-globin locus during phase I, the modification was strongly re-established at the γ -globin promoters and at HS3 after removal of the drug (Supplemental Figure S3 ).
G9a establishment of H3K9me2 is localized in silenced domains of euchromatin. 23 The strongest accumulation of H3K9me2 in the β-globin locus of adult erythroid cells was detected at the silenced γ -globin genes in agreement with previous observations. 24 Higher H3K9me2 at the fetal compared to adult genes was also reported in primary human bone marrow erythroblasts in the absence of ex vivo culture. 28 Inhibition of G9a methyltransferase activity caused a strong decrease of H3K9 dimethylation throughout the locus but this was especially notable at the γ -globin gene promoter associated with reactivation of γ -globin gene expression, further supporting a repressive role for G9a in regulation of hemoglobin production. Surprisingly, the decrease in H3K9 dimethylation at the adult globin gene promoters after UNC0638 treatment was associated with repression of these genes suggesting that H3K9me2 does not play a significant role in regulation of the adult β-globin genes. This notion is supported by previous
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From experiments demonstrating that activation of the mouse adult β -globin gene is not associated with changes in H3K9me2 levels at the gene promoter. 9 Besides H3K9me2, we observed a moderate decrease in H3K27me2 across the β-globin locus after inhibition of G9a methyltransferase activity. If this is a direct or indirect effect remains unclear as recent data suggest G9a methyltransferase activity is not directly linked to the H3K27me2 mark in vivo. [29] [30] [31] Besides the well-established role of G9a in gene repression, several lines of evidence support its methyltransferase independent role in activation of gene expression. 12 In the mouse β-globin locus, G9a activates adult globin gene expression independently from methyltransferase activity through interaction with mediator complex. How G9a recruitment is altered as a result of UNC0638 treatment remains an open question. G9a is recruited to CpG islands (CGIs) genome wide and spreads from these sites to establish H3K9me2 domains encompassing silenced chromatin. 16 However, G9a is recruited to the mouse β -globin locus LCR HS2 site, which is not a CGI, and spreads in the locus from that site. 9 G9a occupancy at HS2 depends on NF-E2. Our data suggest that recruitment of G9a within the LCR and spreading through the human β-globin locus are unaffected by UNC0638 and loss of its methyltransferase activity. Rather, it is the specific localization of G9a at either fetal or adult globin genes that is affected by UNC0638, which correlates with gene expression. G9a also interacts with PolII 9 and participates in a gene activating complex with mediator. 10 We speculate that increased occupancy of G9a at the fetal γ -globin promoters is emblematic of occupancy by such activating complexes. However, the order of events in localization of this complex at the γ-globin promoters with respect to decreased H3K9me2, increased LDB1 complex occupancy and LCR looping remains unclear. Further, since G9a also methylates non-histone chromatin remodeling factors, 32, 33 regulation of other globin gene regulatory proteins might be considered.
Expression of both the adult and fetal globin genes is regulated by the LDB1 containing protein complex through facilitating loop formation between the LCR and expressed genes. 5, 6 There is a tight correlation between globin gene expression status, LDB1 protein complex occupancy and looping with the LCR. 21 Recently, the primary role of LDB1 in regulation of the globin genes expression was confirmed by artificial tethering of the LDB1 dimerization domain to silenced γ -globin gene promoters with subsequent activation of its expression in adult erythroid cells. 27 In agreement with these observations, we found that H3K9me2 elimination from the 
35
Inhibition of G9a methyltransferase activity in adult erythroid cells of patients with hemoglobinopathies such as sickle cell disease and β-thalassemia should cause increased expression of HbF production with subsequent beneficial therapeutic effect. 36 Although, poor in vivo pharmacokinetic properties of UNC0638 may preclude its use as a drug, additional G9a targeting compounds are being developed including UNC0642 with similar inhibitory properties and improved in vivo stability. 37 In addition to the identification and development of UNC0638-related compounds, recognition of the role of H3K9 methylation in globin gene regulation could advance mechanistic studies of existing or alternate drugs that augment HbF expression including cytidine derivatives. While 5-Aza-2'-deoxycytidine is thought to act primarily via DNA demethylation, its epigenetic effects include strong reduction of H3K9me2 histone marks at gene promoters. 38 In baboons treated with 5-Aza-2'-deoxycytidine by subcutaneous injection, changes in several histone modifications at the globin genes were detected, but H3K9me2 was not studied. 39 Alternatively, loss of G9a/GLP activity may direct DNA methylation, 40 or affect the activity of LSD1, another therapeutic target for induction of fetal hemoglobin. 41 Of note, REST-mediated gene repression involves co-localization of G9a, LSD1, and histone deacetylases 
